PYXS

Pyxis Oncology, Inc. [PYXS] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

PYXS Stock Summary

Top 10 Correlated Stocks

PYXS


In the News

06:35 26 Mar 2023 PYXS

Pyxis Oncology to Present at H.C. Wainwright Preclinical Cancer Drug Discovery Conference

CAMBRIDGE, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), an oncology company focused on developing next-generation therapeutics for difficult-to-treat cancers, today announced that the Company will present at the H.C. Wainwright Preclinical Cancer Drug Discovery - Antibody Drug Conjugates (ADCs) virtual conference. The pre-recorded presentation given by Lara Sullivan, M.D., President and Chief Executive Officer, and Jay Feingold, M.D., Ph.D., Chief Medical Officer, will be available on-demand at 9:00 a.m. ET on Wednesday, June 29, 2022.

06:35 26 Mar 2023 PYXS

Pyxis Oncology Announces Presentations at Upcoming Investor Conferences

CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat cancers, today announced that Lara Sullivan, M.D., President and Chief Executive Officer, and members of the management team will present at the following upcoming investor conferences:

06:35 26 Mar 2023 PYXS

Pyxis Oncology to Host Corporate Update Conference Call and Webcast on March 29, 2022

CAMBRIDGE, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset, multi-modality company focused on developing next-generation therapeutics for difficult to treat cancers, today announced it will host a conference call and live webcast on Tuesday, March 29, 2022 at 8:00 a.m. ET to discuss recent corporate updates.

08:00 26 Mar 2023 PYXS

Pyxis Oncology to Present at the Jefferies London Healthcare Conference

CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), today announced that management will present at and host one-on-one investor meetings during the virtual portion of the Jefferies London Healthcare Conference, taking place November 18-19, 2021. The presentation will be available on-demand for attendees during the virtual conference beginning on November 18, 2021. A replay of the presentation will be available on the Events and Presentation page on Pyxis Oncology's website following the conference's conclusion.

PYXS Financial details

Company Rating
Neutral
Market Cap
91.89M
Income
-59.05M
Revenue
0
Book val./share
4.87
Cash/share
5.43
Dividend
-
Dividend %
-
Employees
73
Optionable
No
Shortable
Yes
Earnings
22 Mar 2023
P/E
-0.61
Forward P/E
-
PEG
0.08
P/S
-
P/B
0.38
P/C
0.41
P/FCF
-0.9
Quick Ratio
10.4
Current Ratio
10.62
Debt / Equity
0.31
LT Debt / Equity
0.12
-
-
EPS (TTM)
-1.82
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
16.4%
SMA50
54.93%
SMA100
22.91%
Inst Own
60.54%
Inst Trans
0.63%
ROA
-53%
ROE
-53%
ROC
-0.5%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
41.58M
Shs Float
0
-
-
-
-
Target Price
-
52W Range
1.1-5.0
52W High
-55.8%
52W Low
+121%
RSI
53.39
Rel Volume
7.06
Avg Volume
136.22K
Volume
961.88K
Perf Week
9.95%
Perf Month
45.39%
Perf Quarter
12.18%
Perf Half Y
11.62%
-
-
-
-
Beta
-
-
-
Volatility
0.24%, 0.31%
Prev Close
14.51%
Price
2.21
Change
3.76%

PYXS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
0000
Net income per share
-0.13-0.58-8.950
Operating cash flow per share
-0.1-0.46-4.16-2.7
Free cash flow per share
-0.1-0.53-4.22-2.9
Cash per share
0.90.3732.355.43
Book value per share
-0.13-0.7130.774.87
Tangible book value per share
-0.13-0.7130.774.87
Share holders equity per share
-0.13-0.7130.774.87
Interest debt per share
00.040.020.57
Market cap
290.07M290.07M93.17M44.26M
Enterprise value
270.4M282.77M-181.56M-116.11M
P/E ratio
-104.64-22.61-1.230
Price to sales ratio
0000
POCF ratio
-129.56-28.77-2.64-0.5
PFCF ratio
-129.56-25.08-2.6-0.46
P/B Ratio
-100.93-18.540.360.28
PTB ratio
-100.93-18.540.360.28
EV to sales
0000
Enterprise value over EBITDA
-97.55-22.882.410.95
EV to operating cash flow
-120.77-28.045.141.3
EV to free cash flow
-120.77-24.455.061.21
Earnings yield
-0.01-0.04-0.820
Free cash flow yield
-0.01-0.04-0.38-2.16
Debt to equity
-7.89-1.650.070.31
Debt to assets
1.152.540.070.24
Net debt to EBITDA
7.10.593.651.31
Current ratio
26.882.214.95.9
Interest coverage
0000
Income quality
0.810.790.460.74
Dividend Yield
0000
Payout ratio
0000
Sales general and administrative to revenue
0000
Research and developement to revenue
0000
Intangibles to total assets
0000
Capex to operating cash flow
00.150.020.07
Capex to revenue
0000
Capex to depreciation
0-3.16-0.83-9.03
Stock based compensation to revenue
0000
Graham number
0.613.0678.690
ROIC
0.141.820.250
Return on tangible assets
-0.14-1.26-0.270
Graham Net
-0.14-0.8130.143.9
Working capital
18.97M4.41M259.97M154.98M
Tangible asset value
-2.87M-15.65M261.31M160.82M
Net current asset value
-2.98M-17.69M259.97M136.06M
Invested capital
-0.01-0.0500.12
Average receivables
0000
Average payables
0784K6.51M9.52M
Average inventory
0000
Days sales outstanding
0000
Days payables outstanding
0000
Days of inventory on hand
0000
Receivables turnover
0000
Payables turnover
0000
Inventory turnover
0000
ROE
0.960.82-0.290
Capex per share
0-0.07-0.06-0.19

Quarterly Fundamentals Overview

Last date of statement is 2022-12-31 for Q4

Metric History 2021-12-312022-03-312022-06-302022-09-30 2022-12-31
Revenue per share
00000
Net income per share
-1.85-0.970-0.850
Operating cash flow per share
-0.8-0.86-0.73-0.63-2.08
Free cash flow per share
-0.81-0.86-0.73-0.76-2.15
Cash per share
8.667.656.886.15.43
Book value per share
8.237.236.535.84.87
Tangible book value per share
8.237.236.535.84.87
Share holders equity per share
8.237.236.535.84.87
Interest debt per share
0.0100.480.520.57
Market cap
348.12M130.56M77.23M64.15M44.26M
Enterprise value
73.39M-116.53M-130.44M-118.34M-116.11M
P/E ratio
-1.48-1.040-0.580
Price to sales ratio
00000
POCF ratio
-13.71-4.72-3.26-3.12-0.64
PFCF ratio
-13.5-4.69-3.24-2.58-0.62
P/B Ratio
1.330.560.360.340.28
PTB ratio
1.330.560.360.340.28
EV to sales
00000
Enterprise value over EBITDA
-1.263.735.14.421.23
EV to operating cash flow
-2.894.215.55.761.69
EV to free cash flow
-2.854.195.474.771.64
Earnings yield
-0.17-0.240-0.430
Free cash flow yield
-0.07-0.21-0.31-0.39-1.6
Debt to equity
0.070.080.140.190.31
Debt to assets
0.070.080.130.160.24
Net debt to EBITDA
4.717.928.126.821.7
Current ratio
14.913.115.1910.625.9
Interest coverage
0-3.49K0-39.490
Income quality
0.430.880.930.740.74
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.020.010.010.210.03
Capex to revenue
00000
Capex to depreciation
-1.83-0.92-0.81-21.33-4.19
Stock based compensation to revenue
00000
Graham number
18.512.56010.530
ROIC
0.060.1300.160
Return on tangible assets
-0.21-0.120-0.120
Graham Net
8.077.055.945.023.9
Working capital
259.97M232.07M211.68M183.71M154.98M
Tangible asset value
261.31M233.51M211.97M188.75M160.82M
Net current asset value
259.97M232.07M196M167.66M136.06M
Invested capital
000.070.090.12
Average receivables
00000
Average payables
6.94M7M4.94M6.66M6.3M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.22-0.130-0.150
Capex per share
-0.0100-0.13-0.06

PYXS Frequently Asked Questions

What is Pyxis Oncology, Inc. stock symbol ?

Pyxis Oncology, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol PYXS

What is Pyxis Oncology, Inc. stock quote today ?

Pyxis Oncology, Inc. stock price is $2.21 today.

Is Pyxis Oncology, Inc. stock public?

Yes, Pyxis Oncology, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Top Correlated Stocks
Similar Market Cap